Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 1, 2015, Pages 69-73

  Rinck Junior, José Augusto ^a   Oliveira, Cristiane ^a   Lourenço, Gustavo Jacob ^a   Sagarra, Regina Aparecida Martinho ^a   Derchain, Sophie Françoise Mauricette ^a   Segalla, José Getulio ^b   Lima, Carmen Silvia Passos ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Amaral Carvalho Hospital   (Brazil)

Author keywords

COL18A1 D104N; Epithelial ovarian cancer; Risk; VEGF C936T

Indexed keywords

GENOMIC DNA; VASCULOTROPIN C; COL19A1 PROTEIN, HUMAN; FIBRIL ASSOCIATED COLLAGEN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COLLOID CARCINOMA; COMPARATIVE STUDY; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; MALE; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROMOTER REGION; RISK FACTOR; TRANSITIONAL CELL CARCINOMA; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FIBRIL-ASSOCIATED COLLAGENS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84925031246     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1786-0     Document Type: Article

References (33)

1. Abdollahi A, Hahnfeldt P, Maercker C et al (2004) Endostatin’s antiangiogenic signaling network. Mol Cell 13(5):649–663
2. American Joint Committee on Cancer (2002) Ovary. In: AJCC cancer staging manual, 6th edn. Springer, New York, pp 275–284
3. Banerjee S, Kaye S (2011) The role of targeted therapy in ovarian cancer. Eur J Cancer 47(Suppl 3):S116–S130. doi:10.1016/S0959-8049(11):70155-1
4. Baxter SW, Thomas EJ, Campbell IG (2001) GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis 22(1):63–65. doi:10.1093/carcin/22.1.63
5. Belotti D, Calcagno C, Garofalo A et al (2008) Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res 6(4):525–534. doi:10.1158/1541-7786.MCR-07-0366
6. Cannistra SA, Gershenson DM, Recht A (2011) Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: De Vita VT Jr, Lawrence TS, Rosenberg SA (eds) Cancer: principles & practice of oncology, 9th edn. Lippincott Willimas & Wilkins, Philadelphia, pp 1368–1391
7. Chang Z, Choon A, Friedl A (1999) Endostatin binds to blood vessels in situ independent of heparan sulphate and does not compete for fibroblast growth factor-2 binding. Am J Pathol 155:71–76
8. Dixelius J, Larsson H, Sasaki T et al (2000) Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95:3403–3411
9. Engels K, du Bois A, Harter P et al (2009) VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. J Clin Pathol 62(5):448–454. doi:10.1136/jcp.2008.063859
10. Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175:409–416
11. Gershenson DM, Sun CC, Bodurka D et al (2009) Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114:48–52. doi:10.1016/j.ygyno.2009.03.001
12. Hankinson SE, Hunter DJ, Colditz GA et al (1993) Tubal ligation hysterectomy, and risk of ovarian cancer: a prospective study (comment). JAMA 270:2813–2818. doi:10.1001/jama.1993.03510230051034
13. Hata K, Fujiwaki R, Nakayama K et al (2001) Expression of the endostatin gene in epithelial ovarian cancer. Clin Cancer Res 7(8):2405–2409
14. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1127. doi:10.1200/JCO.2005.06.081
15. Hollingsworth HC, Kohn EC, Steinberg SM et al (1995) Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33–41
16. Iughetti P, Suzuki O, Godoi PH et al (2001) A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 61(20):7375–7378
17. Jakubowska A, Gronwald J, Menkiszak J et al (2008) The VEGF_936_C > T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett 262:71–76. doi:10.1016/j.canlet.2007
18. Jiang J, Chen W, Zhuang R et al (2010) The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro. J Cancer Res Clin Oncol 136(6):873–881. doi:10.1007/s00432-009-0728-8
19. Kim YM, Hwang S, Pyun BJ et al (2002) Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277:27872–27879
20. Konac E, Onen HI, Metindir J et al (2007) Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers. DNA Cell Biol 26(7):453–463
21. Krippl P, Langsenlehner U, Renner W et al (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106:468–471. doi:10.1002/ijc.11238
22. Li Y, Wang Y, Kang S et al (2010) Association of vascular endothelial growth factor gene polymorphisms with susceptibility to epithelial ovarian cancer. Int J Gynecol Cancer 20(5):717–723
23. Lin GT, Tseng HF, Yang CH et al (2009) Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS 13:165–172. doi:10.1089/omi.2008.0050
24. Lourenço GJ, Cardoso-Filho C, Gonçales NS et al (2006) A high risk of occurrence of sporadic breast cancer in individuals with the 104NN polymorphism of the COL18A1 gene. Breast Cancer Res Treat 100(3):335–338. doi:10.1007/s10549-006-9259-z
25. O’Reilly MS, Boehm T, Shing Y et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285
26. Oliveira C, Lourenço GJ, Silva PMR et al (2011) Polymorphisms in the 5′ and 3′-untranslated region of the VEGF gene are associated with breast cancer risk and clinicopathologic characteristics. Tumor Biol 32(2):295–301. doi:10.1007/s13277-010-0121-x
27. Omura GA, Brady MF, Homesley HD et al (1991) Long term follow up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9:1138–1150
28. Renner W, Kotschan S, Hoffmann C et al (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37(6):443–448. doi:10.1159/000054076
29. Shen GH, Ghazizadeh M, Kawanami O et al (2000) Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83(2):196–203. doi:10.1054/bjoc.2000.1228
30. Spurdle AB, Webb PM, Purdie DM et al (2001) Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis 22(1):67–72. doi:10.1093/carcin/22.1.67
31. Vincenti V, Cassano C, Rocchi M et al (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93(8):1493–1495
32. Wang Z, Wen P, Luo X et al (2014) Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population. Tumour Biol 35(4):3605–3610. doi:10.1007/s13277-013-1475-1477
33. World Health Organization (2003) Tumors of the breast and female genital organs. International Agency for Research in Cancer, Lyon